NCT01347801View on ClinicalTrials.gov

Mechanisms of Insulin Resistance in Critical Illness: Role of Systemic Inflammation and GLP-1

NACompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

March 31, 2011

Primary Completion Date

September 30, 2014

Study Completion Date

September 30, 2014

Conditions
Hypoglycaemia
Interventions
DRUG

GLP-1

GLP-1 1,2pmol/kg/min i.v. infusion for 4 hours

DRUG

Placebo (Saline)

Normal saline (NaCl 0,9%)

DRUG

TNF-alfa

1000ng/m2 BSA/hour i.v. infusion for 4-6 hours

OTHER

OGTT

Oral glucose tolerance test with 75 g glucose

OTHER

IVGTT

Intravenous glucose tolerance test with infusion of 20% glucose matching the glucose profile of the corresponding OGTT

Trial Locations (2)

2100

Centre of Inflammation and Metabolism - Rigshospitalet 7641, Copenhagen

2400

University of Copenhagen, Copenhagen

Sponsors

Collaborators (1)

Novo Nordisk A/S
All Listed Sponsors
collaborator

University of Copenhagen

OTHER

collaborator

Novo Nordisk A/S

INDUSTRY

lead

Rigshospitalet, Denmark

OTHER

NCT01347801 - Mechanisms of Insulin Resistance in Critical Illness: Role of Systemic Inflammation and GLP-1 | Biotech Hunter | Biotech Hunter